"Janus Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit JANUS KINASES.
Descriptor ID |
D000075242
|
MeSH Number(s) |
D27.505.519.389.755.500
|
Concept/Terms |
Janus Kinase Inhibitors- Janus Kinase Inhibitors
- Inhibitors, Janus Kinase
- Kinase Inhibitors, Janus
- JAK Inhibitors
- Inhibitors, JAK
|
Below are MeSH descriptors whose meaning is more general than "Janus Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Janus Kinase Inhibitors".
This graph shows the total number of publications written about "Janus Kinase Inhibitors" by people in this website by year, and whether "Janus Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2016 | 0 | 1 | 1 |
2017 | 0 | 1 | 1 |
2019 | 1 | 1 | 2 |
2020 | 4 | 2 | 6 |
2021 | 3 | 0 | 3 |
2022 | 7 | 2 | 9 |
2023 | 10 | 0 | 10 |
2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Janus Kinase Inhibitors" by people in Profiles.
-
JAK/STAT defects and immune dysregulation, and guiding therapeutic choices. Immunol Rev. 2024 Mar; 322(1):311-328.
-
Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study. Bone Marrow Transplant. 2024 02; 59(2):196-202.
-
Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Adv. 2023 10 10; 7(19):5835-5842.
-
New era for myelofibrosis treatment with novel agents beyond Janus kinase-inhibitor monotherapy: Focus on clinical development of BCL-XL /BCL-2 inhibition with navitoclax. Cancer. 2023 11 15; 129(22):3535-3545.
-
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study. Lancet Haematol. 2023 Sep; 10(9):e735-e746.
-
Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials. Blood Adv. 2023 07 25; 7(14):3582-3591.
-
The role of therapy in the outcome of patients with myelofibrosis. Cancer. 2023 09 15; 129(18):2828-2835.
-
Cytopenic myelofibrosis: prevalence, relevance, and treatment. Expert Opin Pharmacother. 2023 Jun; 24(8):901-912.
-
Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies. Cancer Med. 2023 05; 12(9):10612-10624.
-
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Na?ve Myelofibrosis. J Clin Oncol. 2023 Nov 10; 41(32):4993-5004.